Gong Ping, Zhang Jingke, Huang Chengwu, Lok U-Wai, Tang Shanshan, Liu Hui, DeRuiter Ryan, Petersen Kendra, Knoll Kate, Robinson Kathryn, Watt Kymberly, Callstrom Matthew, Chen Shigao
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Ultrasound, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
J Ultrasound Med. 2025 Jan;44(1):77-85. doi: 10.1002/jum.16582. Epub 2024 Sep 24.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%-30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost-effective, widely accessible, and precise biomarkers to evaluate liver steatosis. This study aims to assess and compare the diagnostic performance of a novel reference frequency method-based ultrasound attenuation coefficient estimation (ACE) in both fundamental (RFM-ACE-FI) and harmonic (RFM-ACE-HI) imaging for detecting and grading liver steatosis.
An Institutional Review Board-approved prospective study was carried out between December 2018 and October 2022. A total number of 130 subjects were enrolled in the study. The correlation between RFM-ACE-HI values and magnetic resonance imaging proton density fat fraction (MRI-PDFF), as well as between RFM-ACE-FI values and MRI-PDFF were calculated. The diagnostic performance of RFM-ACE-FI and RFM-ACE-HI was evaluated using receiver operating characteristic (ROC) curve analysis, as compared to MRI-PDFF. The reproducibility of RFM-ACE-HI was assessed by interobserver agreement between two sonographers.
A strong correlation was observed between RFM-ACE-HI and MRI-PDFF, with R = 0.88 (95% confidence interval [CI]: 0.83-0.92; P < .001), while the correlation between RFM-ACE-FI and MRI-PDFF was R = 0.65 (95% CI: 0.50-0.76; P < .001). The area under the ROC (AUROC) curve for RFM-ACE-HI in staging liver steatosis grades of S ≥ 1 and S ≥ 2 was 0.97 (95% CI: 0.91-0.99; P < .001) and 0.98 (95% CI: 0.93-1.00; P < .001), respectively, and 0.76 (95% CI: 0.65-0.85) and 0.80 (95% CI: 0.70-0.88) for RFM-ACE-FI, respectively. Great reproducibility was achieved for RFM-ACE-HI, with an interobserver agreement of R = 0.97 (95% CI: 0.94-0.99; P < .001).
The novel RFM-ACE-HI method offered high liver steatosis diagnostic accuracy and reproducibility, which has important clinical implications for early disease intervention and treatment evaluation.
代谢功能障碍相关脂肪性肝病(MASLD)是西方国家最常见的肝脏疾病,约20%-30%的MASLD患者会进展到严重阶段。迫切需要无创、经济高效、广泛可用且精确的生物标志物来评估肝脂肪变性。本研究旨在评估和比较一种基于新型参考频率方法的超声衰减系数估计(ACE)在基波(RFM-ACE-FI)和谐波(RFM-ACE-HI)成像中检测和分级肝脂肪变性的诊断性能。
2018年12月至2022年10月期间开展了一项经机构审查委员会批准的前瞻性研究。共有130名受试者纳入该研究。计算RFM-ACE-HI值与磁共振成像质子密度脂肪分数(MRI-PDFF)之间以及RFM-ACE-FI值与MRI-PDFF之间的相关性。与MRI-PDFF相比,使用受试者工作特征(ROC)曲线分析评估RFM-ACE-FI和RFM-ACE-HI的诊断性能。通过两名超声检查人员之间的观察者间一致性评估RFM-ACE-HI的可重复性。
观察到RFM-ACE-HI与MRI-PDFF之间存在强相关性,R = 0.88(95%置信区间[CI]:0.83-0.92;P <.001),而RFM-ACE-FI与MRI-PDFF之间的相关性为R = 0.65(95%CI:0.50-0.76;P <.001)。RFM-ACE-HI在分期肝脂肪变性等级S≥1和S≥2时的ROC曲线下面积(AUROC)分别为0.97(95%CI:0.91-0.99;P <.001)和0.98(95%CI:0.93-1.00;P <.001),RFM-ACE-FI的分别为0.76(95%CI:0.65-0.85)和0.80(95%CI:0.70-0.88)。RFM-ACE-HI具有很高的可重复性,观察者间一致性为R = 0.97(95%CI:0.94-0.99;P <.001)。
新型RFM-ACE-HI方法具有较高的肝脂肪变性诊断准确性和可重复性,这对疾病的早期干预和治疗评估具有重要的临床意义。